AC
FULC icon

AXQ Capital’s Fulcrum Therapeutics FULC Stock Holding History

AXQ Capital’s Portfolio FULC Stock Details FULC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$169K Sell
22,043
-9,502
-30% -$88.1K 0.02% 788
2025
Q4 		$357K Buy
+31,545
New +$321K 0.08% 381

Other funds holding FULC

SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return
B
Braidwell Stamford, Connecticut $3B AUM 46.72% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
SL
Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return
FTM
First Turn Management Del Mar, California $895M AUM 261.28% 1-Year Est. Return
Aberdeen Group
Aberdeen Group Edinburgh, United Kingdom $61.9B AUM 29.81% 1-Year Est. Return

AXQ Capital's FULC Position: Q1 2026 in Review

AXQ Capital reduced its Fulcrum Therapeutics (FULC) stake by 30% in Q1 2026, selling an estimated $88.1K and leaving 22,043 shares worth $169K. The position accounts for 0.02% of the portfolio, ranked #788.

AXQ Capital first reported a position in FULC in Q4 2025 and has held it in 2 quarters since. The position peaked at $357K in Q4 2025. 169 funds tracked by Wall St. Rank hold FULC as of Q1 2026.

  • AXQ Capital held 22,043 shares of Fulcrum Therapeutics worth $169K as of Q1 2026.
  • AXQ Capital sold 9,502 Fulcrum Therapeutics shares in Q1 2026, an estimated $88.1K.
  • Fulcrum Therapeutics made up 0.02% of AXQ Capital's portfolio in Q1 2026, its #788 holding.
  • AXQ Capital first reported a position in Fulcrum Therapeutics in Q4 2025 and has held it in 2 quarters since.
  • AXQ Capital's Fulcrum Therapeutics position peaked at $357K in Q4 2025.
  • 169 funds tracked by Wall St. Rank held Fulcrum Therapeutics as of Q1 2026.

Based on AXQ Capital's 13F filing for Q1 2026, filed 13 May 2026.